Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA 2

Olimpia Vincentini, Maria Giovanna Quaranta, Marina Viora, Carlo Agostoni, Marco Silano

Research output: Contribution to journalArticle

Abstract

Background & aims: The cytosolic phospolypase A 2 (cPLA 2) - dependent release of arachidonic acid (AA) from the intra-epithelial lymphocytes plays a pivotal role in arming lymphocytes to cytolysis in the immune response of celiac disease. However, little is known about the role of enterocytes in releasing AA. Docosahexaenoic acid (DHA) is a long chain polyunsaturated fatty acid that counteracts many of the proinflammatory effect of AA. The aims of the present work were to evaluate if: 1) intestinal epithelial cells have a role in the celiac inflammation, releasing AA, and 2) if DHA is able to modulate the celiac inflammation, down-regulating the release of AA. Methods: A human intestinal epithelial cell line (Caco-2) was exposed to gliadin peptides (PT-gl) (500 μg/ml) and DHA (2 μg/ml), both alone and simultaneously up to 24 h. Results: The exposure of those cells to PT-gl alone resulted in an increased AA release, cycloxygenase-2 expression, cPLA 2 activity and prostaglandin E 2 and interleukin-8 release in culture medium, whereas the simultaneous exposure of the cells to DHA and PT-gl prevented the above-mentioned increases. Conclusions: These results suggest that intestinal epithelial cells sustain the celiac inflammation, releasing AA when stimulated with gliadin and that DHA inhibits the AA release by these cells.

Original languageEnglish
Pages (from-to)541-546
Number of pages6
JournalClinical Nutrition
Volume30
Issue number4
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Docosahexaenoic Acids
Celiac Disease
varespladib methyl
Arachidonic Acid
Epithelial Cells
Inflammation
Abdomen
Gliadin
Lymphocytes
In Vitro Techniques
Enterocytes
Prostaglandins E
Unsaturated Fatty Acids
Interleukin-8
Culture Media
Cell Line
Peptides

Keywords

  • Arachidonic acid
  • Celiac disease
  • DHA
  • Intestinal epithelial cells
  • Mucosal inflammation

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Nutrition and Dietetics

Cite this

Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA 2 . / Vincentini, Olimpia; Quaranta, Maria Giovanna; Viora, Marina; Agostoni, Carlo; Silano, Marco.

In: Clinical Nutrition, Vol. 30, No. 4, 08.2011, p. 541-546.

Research output: Contribution to journalArticle

Vincentini, Olimpia ; Quaranta, Maria Giovanna ; Viora, Marina ; Agostoni, Carlo ; Silano, Marco. / Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA 2 . In: Clinical Nutrition. 2011 ; Vol. 30, No. 4. pp. 541-546.
@article{eaa86e98fdaa4c1d92991ece53b16e0c,
title = "Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA 2",
abstract = "Background & aims: The cytosolic phospolypase A 2 (cPLA 2) - dependent release of arachidonic acid (AA) from the intra-epithelial lymphocytes plays a pivotal role in arming lymphocytes to cytolysis in the immune response of celiac disease. However, little is known about the role of enterocytes in releasing AA. Docosahexaenoic acid (DHA) is a long chain polyunsaturated fatty acid that counteracts many of the proinflammatory effect of AA. The aims of the present work were to evaluate if: 1) intestinal epithelial cells have a role in the celiac inflammation, releasing AA, and 2) if DHA is able to modulate the celiac inflammation, down-regulating the release of AA. Methods: A human intestinal epithelial cell line (Caco-2) was exposed to gliadin peptides (PT-gl) (500 μg/ml) and DHA (2 μg/ml), both alone and simultaneously up to 24 h. Results: The exposure of those cells to PT-gl alone resulted in an increased AA release, cycloxygenase-2 expression, cPLA 2 activity and prostaglandin E 2 and interleukin-8 release in culture medium, whereas the simultaneous exposure of the cells to DHA and PT-gl prevented the above-mentioned increases. Conclusions: These results suggest that intestinal epithelial cells sustain the celiac inflammation, releasing AA when stimulated with gliadin and that DHA inhibits the AA release by these cells.",
keywords = "Arachidonic acid, Celiac disease, DHA, Intestinal epithelial cells, Mucosal inflammation",
author = "Olimpia Vincentini and Quaranta, {Maria Giovanna} and Marina Viora and Carlo Agostoni and Marco Silano",
year = "2011",
month = "8",
doi = "10.1016/j.clnu.2011.02.007",
language = "English",
volume = "30",
pages = "541--546",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Docosahexaenoic acid modulates in vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA 2

AU - Vincentini, Olimpia

AU - Quaranta, Maria Giovanna

AU - Viora, Marina

AU - Agostoni, Carlo

AU - Silano, Marco

PY - 2011/8

Y1 - 2011/8

N2 - Background & aims: The cytosolic phospolypase A 2 (cPLA 2) - dependent release of arachidonic acid (AA) from the intra-epithelial lymphocytes plays a pivotal role in arming lymphocytes to cytolysis in the immune response of celiac disease. However, little is known about the role of enterocytes in releasing AA. Docosahexaenoic acid (DHA) is a long chain polyunsaturated fatty acid that counteracts many of the proinflammatory effect of AA. The aims of the present work were to evaluate if: 1) intestinal epithelial cells have a role in the celiac inflammation, releasing AA, and 2) if DHA is able to modulate the celiac inflammation, down-regulating the release of AA. Methods: A human intestinal epithelial cell line (Caco-2) was exposed to gliadin peptides (PT-gl) (500 μg/ml) and DHA (2 μg/ml), both alone and simultaneously up to 24 h. Results: The exposure of those cells to PT-gl alone resulted in an increased AA release, cycloxygenase-2 expression, cPLA 2 activity and prostaglandin E 2 and interleukin-8 release in culture medium, whereas the simultaneous exposure of the cells to DHA and PT-gl prevented the above-mentioned increases. Conclusions: These results suggest that intestinal epithelial cells sustain the celiac inflammation, releasing AA when stimulated with gliadin and that DHA inhibits the AA release by these cells.

AB - Background & aims: The cytosolic phospolypase A 2 (cPLA 2) - dependent release of arachidonic acid (AA) from the intra-epithelial lymphocytes plays a pivotal role in arming lymphocytes to cytolysis in the immune response of celiac disease. However, little is known about the role of enterocytes in releasing AA. Docosahexaenoic acid (DHA) is a long chain polyunsaturated fatty acid that counteracts many of the proinflammatory effect of AA. The aims of the present work were to evaluate if: 1) intestinal epithelial cells have a role in the celiac inflammation, releasing AA, and 2) if DHA is able to modulate the celiac inflammation, down-regulating the release of AA. Methods: A human intestinal epithelial cell line (Caco-2) was exposed to gliadin peptides (PT-gl) (500 μg/ml) and DHA (2 μg/ml), both alone and simultaneously up to 24 h. Results: The exposure of those cells to PT-gl alone resulted in an increased AA release, cycloxygenase-2 expression, cPLA 2 activity and prostaglandin E 2 and interleukin-8 release in culture medium, whereas the simultaneous exposure of the cells to DHA and PT-gl prevented the above-mentioned increases. Conclusions: These results suggest that intestinal epithelial cells sustain the celiac inflammation, releasing AA when stimulated with gliadin and that DHA inhibits the AA release by these cells.

KW - Arachidonic acid

KW - Celiac disease

KW - DHA

KW - Intestinal epithelial cells

KW - Mucosal inflammation

UR - http://www.scopus.com/inward/record.url?scp=79960699348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960699348&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2011.02.007

DO - 10.1016/j.clnu.2011.02.007

M3 - Article

C2 - 21421277

AN - SCOPUS:79960699348

VL - 30

SP - 541

EP - 546

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 4

ER -